Literature DB >> 29190135

AACE/ACE POSITION STATEMENT ON THE USE OF FOLLOW-ON BIOLOGICS AND BIOSIMILARS FOR ENDOCRINE DISEASES.

Vivian A Fonseca, Zachary T Bloomgarden, Samuel Dagogo-Jack, George Grunberger, Daniel Einhorn, Alan J Garber, Yehuda Handelsman, Irl B Hirsch, Guillermo E Umpierrez.   

Abstract

This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position and consensus statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician. ABBREVIATIONS: BPCIA = Biologics Price Competition and Innovation Act; FDA = Food and Drug Administration; FFDC = Federal Food Drug and Cosmetics Act; PHS = Public Health Services Act; TE = therapeutic equivalence.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29190135     DOI: 10.4158/EP-2017-0052

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  2 in total

Review 1.  Update on Biosimilar Insulins: A US Perspective.

Authors:  Rong M Zhang; Ritika Puri; Janet B McGill
Journal:  BioDrugs       Date:  2020-08       Impact factor: 7.744

2.  Biosimilar insulin concepts.

Authors:  Zachary T Bloomgarden
Journal:  J Diabetes       Date:  2022-03-28       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.